Vera Therapeutics, Inc. (VERA) Discusses Interim Results of ORIGIN Phase 3 Trial of Atacicept for IgA Nephropathy Transcript

Core Points - Vera Therapeutics held an investor call and webcast to discuss company updates and future outlook [1] Group 1 - The call was led by Marshall Fordyce, the Founder and CEO of Vera Therapeutics [1]